Recursion Pharmaceuticals has caught the attention of major pharmaceutical companies due to its innovative approach to drug discovery. More recently, nVidia bought $70 Million of shares in $RXRX
Here’s why it’s worth knowing about:
AI-Driven Drug Discovery:
Recursion collaborates with major biopharma companies to reduce research and development (R&D) costs and timelines. It employs AI-enabled methods to identify promising biological targets and molecules. By using digital chemistry and machine learning, Recursion calculates potential drug development targets efficiently.
Massive Data Repository:
Recursion maintains an extensive database with over 3.1 trillion relationships between chemical and biological components. This data helps identify potential drug targets and streamline the drug discovery process.
Recent Acquisitions:
Recursion recently acquired AI-related biotechs, Cyclica and Valence, which will enhance its drug discovery capabilities. These acquisitions aim to make Recursion even more effective at identifying drug targets and collaborating with pharmaceutical companies1.
Existing Collaborations:
As we pointed out, powerful players like Roche and Bayer are already among Recursion’s patrons. Collaborating with Recursion allows these companies to leverage AI-driven approaches for drug discovery2.
Rare Disease Pipeline:
Recursion also has its own development pipeline, including three programs in phase 2 clinical trials for rare diseases. For example, one program targets neurofibromatosis type 2, a condition affecting only 33,000 people worldwide. These pipeline projects could significantly boost Recursion’s revenue in the long term
- Recursion Pharmaceuticals (RXRX on the Nasdaq)
- offers a unique blend of AI-driven drug discovery, a vast data repository, and promising collaborations, making it an attractive partner for big pharmaceutical companies